Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 3Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Papillomavirus Infections 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Colorectal Neoplasms 1

Interventions

Carboplatin 156Paclitaxel 154Bevacizumab 96Cyclophosphamide 61Gemcitabine 46olaparib 45Cisplatin 45Topotecan 44niraparib 40liposomal doxorubicin 40pembrolizumab 38Surveys and Questionnaires 33Filgrastim 31Hyperthermic Intraperitoneal Chemotherapy 29Docetaxel 27Taxes 25Blood Specimen Collection 24fludarabine 23Drug Therapy 23Cytoreduction Surgical Procedures 23Peripheral Blood Stem Cell Transplantation 21Etoposide 21Doxorubicin 21Magnetic Resonance Spectroscopy 20durvalumab 17Specimen Handling 17Albumin-Bound Paclitaxel 17Immunoglobulin G 15Disulfides 15Letrozole 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Ovarian Neoplasms × utomilumab × Clear all
NCT03318900 2024-11-07

T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
5 enrolled 8 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡